GSK Q3 FY 2023-24 revenue at Rs. 805 Cr
The company is committed to a new category development in areas like adult Immunization with products like Shingrix to make a positive impact to the lives of the patients in India
The company is committed to a new category development in areas like adult Immunization with products like Shingrix to make a positive impact to the lives of the patients in India
General Medicine grows 5% and Vaccines 10% led by Shingrix
QS-21 in blockbuster Shingles vaccine, first vaccine approved for Malaria, promising RSV phase III candidate, and Covid-19 applications.
Subscribe To Our Newsletter & Stay Updated